Nuova valutazione del felbamato nel trattamento di pazienti con epilessia farmacoresistente

Translated title of the contribution: Felbamate: A new evaluation in refractory epileptic patients

L. M. Specchio, A. La Neve, A. Spinelli, G. Boero, N. Specchio

Research output: Contribution to journalArticle

Abstract

FBM add-on open-label treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy, 4 Lennox-Gastaut syndrome). FBM was titrated up to the maximal tolerated dose or satisfactory clinical control. Blood parameters of liver and bone marrow function were checked every fortnight. 6 pts showed a seizure reduction greater than 50% and 2 pts were seizure-free over a period ranging 12 to 24 months, 8 pts dropped-out for adverse effects. In 3 cases an increase of serum transaminase and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found.

Original languageItalian
Pages (from-to)313-315
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number106-107
Publication statusPublished - 1999

Fingerprint

felbamate
Seizures
Maximum Tolerated Dose
Partial Epilepsy
Transaminases
Alkaline Phosphatase
Epilepsy
Bone Marrow
Liver
Serum
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Nuova valutazione del felbamato nel trattamento di pazienti con epilessia farmacoresistente. / Specchio, L. M.; La Neve, A.; Spinelli, A.; Boero, G.; Specchio, N.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 106-107, 1999, p. 313-315.

Research output: Contribution to journalArticle

@article{bd2c750a047b45aeacdd0b4e46299115,
title = "Nuova valutazione del felbamato nel trattamento di pazienti con epilessia farmacoresistente",
abstract = "FBM add-on open-label treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy, 4 Lennox-Gastaut syndrome). FBM was titrated up to the maximal tolerated dose or satisfactory clinical control. Blood parameters of liver and bone marrow function were checked every fortnight. 6 pts showed a seizure reduction greater than 50{\%} and 2 pts were seizure-free over a period ranging 12 to 24 months, 8 pts dropped-out for adverse effects. In 3 cases an increase of serum transaminase and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found.",
keywords = "Add-on treatment, Felbamate, Refractory epilepsy",
author = "Specchio, {L. M.} and {La Neve}, A. and A. Spinelli and G. Boero and N. Specchio",
year = "1999",
language = "Italian",
pages = "313--315",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "106-107",

}

TY - JOUR

T1 - Nuova valutazione del felbamato nel trattamento di pazienti con epilessia farmacoresistente

AU - Specchio, L. M.

AU - La Neve, A.

AU - Spinelli, A.

AU - Boero, G.

AU - Specchio, N.

PY - 1999

Y1 - 1999

N2 - FBM add-on open-label treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy, 4 Lennox-Gastaut syndrome). FBM was titrated up to the maximal tolerated dose or satisfactory clinical control. Blood parameters of liver and bone marrow function were checked every fortnight. 6 pts showed a seizure reduction greater than 50% and 2 pts were seizure-free over a period ranging 12 to 24 months, 8 pts dropped-out for adverse effects. In 3 cases an increase of serum transaminase and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found.

AB - FBM add-on open-label treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy, 4 Lennox-Gastaut syndrome). FBM was titrated up to the maximal tolerated dose or satisfactory clinical control. Blood parameters of liver and bone marrow function were checked every fortnight. 6 pts showed a seizure reduction greater than 50% and 2 pts were seizure-free over a period ranging 12 to 24 months, 8 pts dropped-out for adverse effects. In 3 cases an increase of serum transaminase and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found.

KW - Add-on treatment

KW - Felbamate

KW - Refractory epilepsy

UR - http://www.scopus.com/inward/record.url?scp=0033493886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033493886&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0033493886

SP - 313

EP - 315

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 106-107

ER -